Statement: patients with Phosphoinositide 3-kinase inhibitor based treatments are ineligible for the primary trial
Primary_evidence: Inclusion Criteria:   Pathologically and radiologically confirmed metastatic triple negative breast cancer   Up to two prior lines of chemotherapy for metastatic breast cancer   Availability of a representative tumor specimen   At least one measurable lesion Exclusion Criteria:   Have received previous treatment with PI3K inhibitors   Symptomatic central nervous system (CNS) metastases (controlled and asymptomatic CNS metastases are acceptable)   Concurrent malignancy or has a malignancy within 3 years of study enrollment   Any of the following mood disorders: active major depressive episode, bipolar disorder, obsessive-compulsive disorder, schizophrenia, history of suicidal attempt or ideation, homicidal ideation, greater than or equal to Common Toxicity Criteria for Adverse Events (CTCAE) grade 3 anxiety   Concurrently using other approved or investigational antineoplastic agent and/or chemotherapy within 21 days prior to enrollment in this study   Has received radiation therapy within 28 days prior to enrollment in this study or has not recovered from side effects of such therapy   Major surgery within 28 days of starting therapy or has not recovered from major side effects of a previous surgery   Poorly controlled diabetes mellitus   History of cardiac dysfunction   Currently receiving treatment with QT prolonging medication and the treatment cannot be discontinued or switched to a different medication   Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of BKM120   Receiving chronic treatment with steroids or another immunosuppressive agent   Other concurrent severe and/or uncontrolled medical condition that would contraindicate participation in this study   History of non-compliance to a medical regimen   Currently being treated with drugs known to be moderate or strong inhibitors or inducers of isoenzyme Cytochrome P450, family 3, subfamily A (CYP3A)   Known history of human immunodeficiency virus (HIV)   Pregnant or breastfeeding   Unwilling to observe total abstinence or to use double barrier method for birth control throughout trial